Navigation Links
First targeted and programmable nanomedicine to show clinical antitumor effects published

Cambridge, MA, April 4, 2012 BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, that are capable of up to a ten-fold increase in drug concentration at tumor sites, has published preclinical and clinical data in Science Translational Medicine showing promising effects in solid tumors and successful clinical translation of BIND-014, the first targeted and programmed nanomedicine to enter human clinical studies.

In the paper titled "Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile," BIND scientists describe BIND-014's ability to concentrate in tumors and provide preclinical and clinical data demonstrating efficacy, safety and pharmacological properties that are superior to and highly differentiated from the parent chemotherapeutic drug, docetaxel. BIND-014 is the first clinical-stage targeted therapeutic nanoparticle with programmable pharmacological properties, including particle circulation time, pharmacokinetic profile, biodistribution and release profile. BIND-014 has been shown to effectively target a receptor expressed in tumors to achieve high drug concentrations at the site of disease.

"These seminal data on BIND's first clinical stage Accurin, BIND-014, demonstrates for the first time that it is possible to generate medicines with both targeted and programmable properties that can concentrate the therapeutic effect directly at the site of disease, potentially revolutionizing how complex diseases such as cancer are treated," commented Omid Farokhzad, M.D, BIND Founder and Associate Professor, Harvard Medical School. "BIND's data are a giant leap forward in achieving the true promise of nanomedicine by enabling the design of therapeutics with highly-differentiated efficacy and safety that go above and beyond the capabilities of traditional drug design through medicinal chemistry."

"Previous attempts to develop targeted nanoparticles have not translated into clinical success because of the inherent difficulty of designing and scaling up a particle capable of targeting, long-circulation via immune-response evasion, and controlled drug release," commented Robert Langer, Sc.D., BIND Founder and David H. Koch Institute Professor at MIT. "BIND-014 is the first therapeutic of its kind to reach clinical evaluation and has demonstrated an increases of up to ten fold in drug concentration in tumors, which lead to substantially better efficacy and safety. This represents a major advance in cancer therapy and a significant milestone for science, technology and medicine."

Key findings include:

  • Preclinical data including pharmacokinetic characteristics consistent with prolonged circulation and controlled drug release with plasma concentrations remaining up to at least 100-fold higher than conventional docetaxel for over 24 hours, as well as up to a ten-fold increase in intratumoral drug concentrations with prolonged and enhanced tumor growth suppression in multiple tumor models compared with conventional docetaxel.
  • Initial clinical data in a heavily pretreated patient population with 17 patients with advanced or metastatic solid tumor cancers indicate that BIND-014 displays pharmacological characteristics consistent with preclinical findings of differentiated pharmacokinetics and accumulation at tumor sites with clinical effects seen at doses as low as 20% of the normally prescribed docetaxel dose and in cancers in which docetaxel has minimal activity..
  • BIND-014 has been administered at doses of up to 75 mg/m2 and dose escalation is ongoing. BIND-014 is generally well tolerated with no new toxicities observed to date.

Study coauthors included scientific and clinical advisors from the Massachusetts Institute of Technology (MIT), Harvard Medical School and Dana-Farber Cancer Institute, Weill Cornell Medical College, the Translational Genomics Research Institute (TGen), Karmanos Cancer Institute and Wayne State University.

"We are very excited about the results of our preclinical development, and successful clinical translation of BIND-014. The initial Phase 1 clinical efficacy and safety in advanced and metastatic cancers demonstrate promise for BIND-014 and provide strong validation for our Accurin platform to develop targeted therapeutics that accumulate at the site of disease to maximize therapeutic effect," said Jeff Hrkach, Ph.D., Senior Vice President, Technology Research and Development of BIND Biosciences. "BIND-014 represents the lead Accurin product to enter the clinic from our pipeline and is an ideal example of the power of our proprietary platform to develop targeted therapeutics."

About BIND-014

BIND-014 is a programmable nanomedicine that combines a targeting ligand and a therapeutic nanoparticle. BIND-014 contains docetaxel, a proven cancer drug which is approved in major cancer indications including breast, prostate and lung, encapsulated in FDA-approved biocompatible and biodegradable polymers. BIND-014 is targeted to prostate specific membrane antigen (PSMA), a cell surface antigen abundantly expressed on the surface of cancer cells and on new blood vessels that feed a wide array of solid tumors. In preclinical cancer models, BIND-014 was shown to deliver up to ten-fold more docetaxel to tumors than an equivalent dose of conventional docetaxel. The increased accumulation of docetaxel at the site of disease translated to marked improvements in antitumor activity and tolerability. BIND-014 is currently in Phase 1 human clinical testing in patients with advanced or metastatic solid tumor cancers (NCT01300533). The early development of BIND-014 was funded in part by the National Cancer Institute and the U.S. National Institutes of Standards and Technology (NIST) under its Advanced Technology Program (ATP).


Contact: Kathryn Morris
The Yates Network

Related biology technology :

1. MiMedx Exceeds Revenue Goal for First Quarter of 2012
2. FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo
3. Expanded Findings for FirstMarks Completed Clinical Study for Predicting Near-Term (2-3 Years) MI
4. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
5. Researchers capture first-ever images of atoms moving in a molecule
6. Be One of the First to Experience Medtrack One View at the AUTM 2012 Annual Meeting
7. First Statewide Biotech Meeting Focuses on Patient Access, Innovation
8. Inaugural Meeting of the FirstMark Scientific Board of Advisors
9. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
10. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
11. Penn researchers build first physical metatronic circuit
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
(Date:6/22/2016)... Research and Markets has announced the addition of the ... The global biomarkers market has ... The market is expected to grow at a five-year compound annual ... $50.6 billion in 2015 to $96.6 billion in 2020. ... to 2020) are discussed. As well, new products approved in 2013 ...
Breaking Biology Technology:
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
Breaking Biology News(10 mins):